Logo Logo

Publications by Rack, B.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 27.

Journal article

Tiefenthaller, A.; Brix, N.; Escudero, Pazos M.; Kost, B.; Rack, B.; Bodungen, V. von; Weissenbacher, T.; Würstlein, R.; Rühle, P.; Gaipl, U.; Harbeck, N.; Belka, C.; Scheithauer, H.; Lauber, K. (2017): Immunologische Aspekte der intraoperativen Radiotherapie beim Mammakarzinom nach brusterhaltender Operation. In: Strahlentherapie und Onkologie, Vol. 193: S72-S72

Jäger, B. A. S.; Neugebauer, J.; Andergassen, U.; Melcher, C.; Schochter, F.; Mouarrawy, D.; Ziemendorff, G.; Clemens, M.; Abel, E. v.; Heinrich, G.; Schüller, K.; Schneeweiss, A.; Fasching, P.; Beckmann, M. W.; Scholz, Ch.; Friedl, T. W. P.; Friese, K.; Pantel, K.; Fehm, T.; Janni, W.; Rack, B. (2017): The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.
In: PLOS One 12(6), e0173593 [PDF, 1MB]

Hein, A.; Rack, B.; Li, L.; Ekici, A. B.; Reis, A.; Lux, M. P.; Cunningham, J. M.; Rübner, M.; Fridley, B. L.; Schneeweiss, A.; Tesch, H.; Lichtenegger, W.; Fehm, T.; Heinrich, G.; Rezai, M.; Beckmann, M. W.; Janni, W.; Weinshilboum, R. M.; Wang, L.; Fasching, P. A.; Häberle, L. (2017): Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study. In: Geburtshilfe und Frauenheilkunde, Vol. 77, No. 6: pp. 651-659

Fehm, T.; Meier-Stiegen, F.; Riethdorf, S.; Schramm, A.; Polasik, A.; Niederacher, D.; Rack, B.; Taran, F.-A.; Müller, V.; Janni, W.; Huober, J. (2017): DETECT V - Detection of the expression of estrogen receptor and human epidermal growth factor receptor 2 on circulating tumor cells from metastatic breast cancer patients. In: Cancer Research, Vol. 77

Janni, W.; Rack, B.; Häberle, L.; Friedl, T. W. P.; Tesch, H.; Lorenz, R.; Jäger, B.; Fehm, T.; Müller, V.; Schneeweiß, A.; Lichtenegger, W.; Blohmer, J.; Beckmann, M. W.; Scholz, C.; Pantel, K.; Trapp, E.; Fasching, P. A. (2017): Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent prognosis. In: Cancer Research, Vol. 77

Polasik, A.; Schramm, A.; Friedl, T. W. P.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Janni, W.; Fehm, T. (2017): DETECT III and IV - Individualized CTC-based therapy of metastatic breast cancer. In: Cancer Research, Vol. 77

Polasik, A.; Schramm, A.; Friedl, T. W. P.; Rack, B.; Trapp, E.; Tzschaschel, M.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Janni, W.; Fehm, T. (2017): The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo-or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer. In: Cancer Research, Vol. 77

Tzschaschel, M. L. J.; Rack, B.; Majunke, L.; Trapp, E. K.; Mahner, S.; Fasching, P. A.; Fehm, T.; Schneeweiss, A.; Friedl, T. W. P.; Polasik, A.; Janni, W.; Alunni-Fabbroni, M. (2017): Profiling miRNA in high risk postoperative early breast cancer patients to detect possible association to correlation with immune system antitumor response. In: Cancer Research, Vol. 77

Tzschaschel, M. L. J.; Rack, B.; Andergassen, U.; Friedl, T. W. P.; Schneeweiss, A.; Müller, V.; Tanja, F.; Pantel, K.; Gade, J.; Lorenz, R.; Rezai, M.; Tesch, H.; Soeling, U.; Polasik, A.; Alunni-Fabbroni, M.; Trapp, E. K.; Mahner, S.; Schindlbeck, C.; Lichtenegger, W.; Beckmann, M. W.; Fasching, P. A.; Janni, W. (2017): Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients Results from the adjuvant SUCCESS A trial. In: Cancer Research, Vol. 77

Schramm, A.; Fried, T. W. P.; Huober, J.; Jäger, B.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pante, K.; Meier-Stiegen, F.; Wimberger, P.; Kümmel, S.; Gebauer, G.; Müller, L.; Janni, W.; Fehm, T. (2016): The DETECT study program - Personalized treatment in metastatic breast cancer based on circulating tumor cells. In: Cancer Research, Vol. 76

Schwentner, L.; Harbeck, N.; Singer, S.; Eichler, M.; Rack, B.; Forstbauer, H.; Wischnik, A.; Scholz, C.; Fink, V.; Huober, J.; Fried, T.; Weissenbacher, T.; Härtl, K.; Kiechle, M.; Janni, W. (2016): Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer Results from the prospective multi-center randomized Adebar trial. In: Cancer Research, Vol. 76

Janni, W.; Schramm, A.; Friedl, T. W. P.; Schochter, F.; Huober, J.; Rack, B.; Alunni-Fabbroni, M.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Krawczyk, N.; Pantel, K.; Fehm, T. (2016): Predictors for discordance in HER2 phenotype between primary tumor and circulating tumor cells in women with metastatic breast cancer. In: Cancer Research, Vol. 76

Ruddy, K. J.; Rack, B.; Schwitulla, J.; Lambrechts, D.; Haeberle, L.; Schramm, A.; Trapp, E.; Scholz, C.; Beutler, A. S.; Ginsburg, E.; Couch, F.; Partridge, A. H.; Wang, L.; Weinshilboum, R. M.; Janni, W.; Vachon, C.; Fasching, P. (2016): Genetic predictors of chemotherapy-related amenorrhea. In: Cancer Research, Vol. 76

Benz, S. C.; Rabizadeh, S.; Cecchi, F.; Beckman, M. W.; Brucker, S. Y.; Hartmann, A.; Golovato, J.; Hembrough, T.; Janni, W.; Rack, B.; Sanborn, J. Z.; Schneeweiss, A.; Vaske, C. J.; Soon-Shiong, P.; Fasching, P. A. (2016): Integrating whole genome sequencing data with RNAseq, pathway analysis, and quantitative proteomics to determine prognosis after standard adjuvant treatment with trastuzumab and chemotherapy in primary breast cancer patients. In: Cancer Research, Vol. 76

Fasching, P. A.; Loibl, S.; Eidtmann, H.; Tesch, H.; Untch, M.; Hilfrich, J.; Schem, C.; Rezai, M.; Gerber, B.; Costa, S. D.; Blohmer, J. U.; Fehm, T. N.; Huober, J.; Liedtke, C.; Müller, V.; Nekljudova, V.; Weber, K.; Rack, B.; Rübner, M.; Wang, L.; Ingle, J. N.; Weinshilboum, R. M.; Minckwitz, G. von; Couch, F. (2016): BRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto study. In: Cancer Research, Vol. 76

Schröder, L.; Rack, B.; Sommer, H.; Koch, J. G.; Weissenbacher, T.; Janni, W.; Schneeweiss, A.; Rezai, M.; Lorenz, R.; Jäger, B.; Schramm, A.; Häberle, L.; Fasching, P. A.; Friedl, T. W. P.; Beckmann, M. W.; Scholz, C. (2016): Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial. In: Geburtshilfe und Frauenheilkunde, Vol. 76, No. 5: pp. 542-550

Schindlbeck, C.; Andergassen, U.; Jückstock, J.; Rack, B.; Janni, W.; Jeschke, U. (2016): Disseminated and circulating tumor cells in bone marrow and blood of breast cancer patients: properties, enrichment, and potential targets. In: Journal of Cancer Research and Clinical Oncology, Vol. 142, No. 9: pp. 1883-1895

Janni, W.; Harbeck, N.; Rack, B.; Augustin, D.; Jückstock, J.; Wischnik, A.; Annecke, K.; Scholz, C.; Huober, J.; Zwingers, T.; Friedl, T. W. P.; Kiechle, M. (2016): Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study. In: British Journal of Cancer, Vol. 114, No. 8: pp. 863-871

Schramm, A.; Friedl, T.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Kümmel, S.; Gebauer, G.; Müller, L.; Janni, W.; Fehm, T. (2016): The DETECT Study Concept - Metastatic breast cancer and circulating tumor cells. In: Oncology Research and Treatment, Vol. 39: pp. 46-47

Janni, W.; Schramm, A.; Friedl, T. W. P.; Schochter, E.; Huober, J.; Rack, B.; Alunni-Fabbroni, M.; Fasching, P. A.; Taran, F.-A.; Hortkopf, A.; Schneeweiss, A.; Mueller, V.; Aktas, B.; Krawczyk, N.; Pantel, K.; Fehm, T. (2016): Factors Predicting Discordance in HER2 Phenotype between Primary Tumor and Circulating Tumor Cells in Women with Metastatic Breast Cancer. In: Oncology Research and Treatment, Vol. 39: p. 47

Tzschaschel, M.; Trapp, E.; Rack, B.; Messina, C.; Mueller, V.; Fehm, T.; Janni, W.; Loehberg, C.; Wimberger, P.; Kolberg, H.-C.; Uleer, C.; Brudler, O.; Sotiriou, C.; Pierga, J.-Y.; Piccart, M.; Ignatiadis, M. (2016): TREAT CTC: An innovative therapy approach to eliminate circulating tumor cells (CTCs). In: Oncology Research and Treatment, Vol. 39: p. 55

Janni, W.; Rack, B.; Fasching, P.; Haeberle, L.; Friedl, T.; Tesch, H.; Lorenz, R.; Neugebauer, J.; Koch, J.; Jaeger, B.; Fehm, T.; Mueller, V.; Schneeweiß, A.; Lichtenegger, W.; Beckmann, M.; Scholz, C.; Pantel, K.; Trapp, E. (2016): Persistence of circulating tumor cells in high risk early breast cancer patients during follow-up care suggests poor prognosis - Results from the adjuvant SUCCESS A trial. In: Cancer Research, Vol. 76

Janning, M.; Müller, V; Vettorazzi, E.; Cubas-Cordova, M.; Gensch, V; Ben Batalla, I; Eulenburg, C. zu; Schem, C.; Fasching, P. A.; Schnappauf, B.; Karn, T.; Fehm, T.; Just, M.; Kühn, T.; Holms, F.; Overkamp, F.; Krabisch, P.; Rack, B.; Denkert, C.; Untch, M.; Tesch, H.; Rezai, M.; Kittel, K.; Pantel, K.; Bokemeyer, C.; Loibl, S.; Minckwitz, G. von; Loges, S. (2016): Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial. In: Oncology Research and Treatment, Vol. 39: p. 185

Jaeger, B. A. S.; Jückstock, Julia K.; Andergassen, Ulrich; Salmen, J.; Schochter, F.; Fink, V.; Alunni-Fabbroni, Marianna; Rezai, M.; Beck, Th.; Beckmann, M. W.; Friese, K.; Friedl, T. W. P.; Janni, W.; Rack, B. (2014): Evaluation of Two Different Analytical Methods for Circulating Tumor Cell Detection in Peripheral Blood of Patients with Primary Breast Cancer. In: BioMed Research International, Vol. 2014, 491459 [PDF, 1MB]

Freydanck, M. K.; Laubender, Rüdiger P.; Rack, B.; Schuhmacher, L.; Jeschke, Udo; Scholz, C. (2012): Two-marker Combinations for Preoperative Discrimination of Benign and Malignant Ovarian Masses. In: Anticancer Research, Vol. 32, No. 5: pp. 2003-2008

Janni, W.; Rack, B.; Gerber, B.; Bauerfeind, I.; Krause, A.; Dian, D.; Sommer, H.; Friese, K. (2006): Pregnancy-associated breast cancer - Special features in diagnosis and treatment. In: Onkologie, No. 3: pp. 107-112 [PDF, 58kB]

Schindlbeck, C.; Kampik, T.; Janni, W.; Rack, B.; Jeschke, U.; Krajewski, S.; Sommer, H.; Friese, K. (2005): Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas. In: Breast Cancer Research 7 [PDF, 228kB]

This list was generated on Thu Nov 21 05:35:12 2019 CET.